News for Alpha Healthcare Acquisition Corp. (AHAC)

- Received U.S. Food and Drug Administration (FDA) approval of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trau

**media[460280]**

Humacyte, Inc. (NASDAQ:NASDAQ:HUMA) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ETCompany ParticipantsLauren Marek - LifeSci Advisors Laura...

Humacyte has promising potential with FDA designations and a pending FDA approval decision for its ATEV product. Learn more about HUMA stock here.

In the future, dental bone graft substitutes are expected for significant developments. Innovations in biomaterials & surgical techniques will improve...

Carmell Corp CEO buys shares worth over $10k

Humacyte's stock price has recently been on an impressive bull run. Read why I could see HUMA achieving a billion-dollar valuation within the next 12 months.

Earnings call: Humacyte anticipates strong market entry post-FDA review

Humacyte, Inc. (NASDAQ:NASDAQ:HUMA) Q1 2024 Earnings Conference Call May 10, 2024 8:00 AM ETCompany ParticipantsTom Johnson - Investor Relations, LifeSci...

-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August...

Operator: Good morning, ladies and gentlemen, and welcome to the Humacyte 2023 Fourth Quarter Year-End Results Conference Call. Currently, all participants are in a listen-only mode.

-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA...

Alpha Healthcare Acquisition Corp. III (ALPA) shareholders have approved a proposed merger with allogeneic biomaterials developer Carmell Therapeutics. Read more here.

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Carmell Therapeutics Merger With Alpha Healthcare Acquisition Corp III July 6, 2023 PRESENTERS Rajiv Shukla Chairman & CEO,...

- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3...

-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in...

Read Research Analysts’ Downgrades for May 31st (AUY, DCOM, DCTH, DRCT, EBMT, EFSC, ETWO, EXLS, FBNC, FDMT) at ETF Daily News